Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303

This publication has 13 references indexed in Scilit:

• Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study
  European Journal of Paediatric Neurology, 2016
• The Stability of Problem Behavior Across the Preschool Years: An Empirical Approach in the General Population
  Journal of Abnormal Child Psychology, 2015
• Behavior and Sleep Problems in Children With a Family History of Autism
  Autism Research, 2013
• Rufinamide in children and adults with Lennox–Gastaut syndrome: First Italian multicenter experience
  Seizure: European Journal of Epilepsy, 2010
• Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: First European experience
  Epilepsy & Behavior, 2009
• Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology
  The Lancet Neurology, 2009
• Treatment of Lennox-Gastaut syndrome: overview and recent findings
  Neuropsychiatric Disease and Treatment, 2008
• Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome
  Neurology, 2008
• Rufinamide
  Neurotherapeutics, 2007
• Childhood Epileptic Encephalopathy with Diffuse Slow Spike‐Waves (otherwise known as “Petit Mal Variant”) or Lennox Syndrome
  Epilepsia, 1966